Triptans in pregnancy

The triptans are a class of tryptamine-based drugs indicated for in the treatment of migraine headaches. The triptans act as serotonin (5-hydroxytriptamine) (5-HT) agonists by binding to various serotonin receptors, causing vasoconstriction and neuronal inhibition to alleviate migraines. There are 7 types of triptans currently available on the U.S. market: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan. The objective of this study was to examine the use and effects of triptans in pregnancy. Although three of the triptans have pregnancy registries maintained by the manufacturer, triptan use in pregnancy has not been extensively studied. Information on the use of sumatriptan during pregnancy is relatively more abundant, because it has been on the market longer than the other triptans and may also have a higher percentage of the market share. There are no data to suggest teratogenicity for any of the triptans, although preterm birth rates appear to be elevated.     

Vaccination in pregnancy

The recent H1N1 influenza pandemic has highlighted the potential for viral infections to cause severe disease in mothers disproportionate to the general population and have deleterious effects on the fetus. Vaccines have been used in pregnant women for over 200 years. Current guidelines recommend vaccination with only inactivated virus due to potential risk to mother and fetus with live vaccine. The exception is during times of pandemic or biological weapons attack, when the risk of life-threatening disease outweighs the risk of vaccination. A paucity of data is available regarding actual risk and mechanisms of live viral vaccine transfer from mother to fetus. Pregnancy-induced changes to the maternal immune system, effects of maternal infection on neonatal immunity, and the role of the placenta in transmission of infection and passive immunity to the fetus are incompletely understood. The aim of this paper is to review available data pertaining to newer vaccines such as the pandemic H1N1 and HPV vaccines in pregnancy, the role of Fc receptors in active transport of immunoglobulin across the placenta, and cytokine activity during maternal infection and after vaccination. We will also discuss potential areas for future research.     

Anticoagulation in pregnancy

The use of anticoagulants during pregnancy for prevention and treatment of venous thromboembolism and prevention of systemic embolism in patients with valvular heart disease presents several problems. This article discusses the complications associated with warfarin, unfractionated heparin, and low-molecular-weight heparin as well as the benefits of each. While a literature review turned up only limited data, the authors extrapolated from existing data recommendations for treatment during pregnancy, finding that oral warfarin should be replaced by heparin during pregnancy, especially from the 6th to the 12th week and near term. In addition, treatment recommendations are provided for different stages of pregnancy, delivery, and postpartum.     

Glucocorticoids in pregnancy

The fetus may be exposed to increased endogenous or synthetic glucocorticoid (GS) exposure in late gestation. Approximately 7% of pregnant women in Europe and North America are treated with synthetic GSs to promote lung maturation in fetuses at risk of preterm delivery. Maternal steroid treatment before preterm delivery is one of the best documented and most cost effective life saving treatments in prenatal medicine but, in certain circumstances, the price of accelerated lung maturity may be loss of brain cells, increased neurodevelopmental disability, intra-uterine growth restriction (IUGR), and an increased risk of preterm delivery, of programming of post-natal hypertension, and of increased post-natal activity in the hypothalamo-pituitary-adrenal (HPA) axis. Placental 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) is the key enzyme which protects the fetus from overexposure to GSs by their oxidation into inactive derivates. We review the evidence for the metabolism of GSs during pregnancy and how endogenous and synthetic GSs cause other changes in the placenta which affect fetal development.     

Adrenomedullin in pregnancy

In this study, we used the animal model of preeclampsia. The blood pressure in animals receiving L-NAME at 25 mg/day were significantly higher compared to that of rats receiving saline solution only. In addition, L-NAME treated rats showed a high fetal mortality as compared with intact rats. Also, we demonstrated infusion of AM reverse the hypertension and decrease in pup mortality induced by L-NAME during pregnancy. We showed that the AM mRNA levels predominantly exists in a high level in the placenta, uterus and ovary as compared with other tissues. These evidences suggest that AM may have a possible important role during pregnancy. In conclusion, the present study suggest that L-NAME-induced elevated blood pressure and increased fetal mortality can be reversed by low dose of AM. Thus AM may play an important role in the regulation of blood pressure, the blood supply to the utero-placental unit and fetal development.     

双胎妊娠妊娠期并发症及妊娠结局分析

目的 探讨双胎妊娠妊娠期并发症对妊娠结局的影响及防预措施.方法 回顾性分析82例双胎妊娠(双胎组)的主要并发症、妊娠结局及同期800例单胎妊娠(单胎组)的病例资料,比较2组孕妇妊娠期并发症、分娩方式、产后出血及新生儿情况.结果 双胎组妊娠期高血压疾病、贫血、胎膜早破(PROM)、早产、胎儿生长受限(FGR)发生率均明显高于单胎组,差异均有统计学意义(P＜0.01).双胎组剖宫产、产后出血、低出生体质量儿、新生儿窒息发生率及围生儿病死率均明显高于单胎组,差异均有统计学意义(P<0.01).结论 加强双胎妊娠的产前监护和指导,积极预防和治疗并发症,对改善双胎妊娠预后和降低围生儿病死率有重要意义.     

双胎妊娠妊娠期并发症及妊娠结局分析

目的探讨双胎妊娠妊娠期并发症对妊娠结局的影响及防预措施。方法回顾性分析82例双胎妊娠（双胎组）的主要并发症、妊娠结局及同期800例单胎妊娠（单胎组）的病例资料,比较2组孕妇妊娠期并发症、分娩方式、产后出血及新生儿情况。结果双胎组妊娠期高血压疾病、贫血、胎膜早破（PROM）、早产、胎儿生长受限（FGR）发生率均明显高于单胎组,差异均有统计学意义（P〈0.01）。双胎组剖宫产、产后出血、低出生体质量儿、新生儿窒息发生率及围生儿病死率均明显高于单胎组,差异均有统计学意义（P〈0.01）。结论加强双胎妊娠的产前监护和指导,积极预防和治疗并发症,对改善双胎妊娠预后和降低围生儿病死率有重要意义。     

Antipsychotic use in pregnancy

Introduction: Antipsychotic medications are being prescribed for a growing number of women with mental illnesses. However, evidence regarding their safety in pregnancy is still insufficient to provide adequate support for clinical practice, creating increasing concern among pregnant women and clinicians.

Areas covered: The aim of this article is to review published data regarding the safety of antipsychotic medications in pregnancy with a focus on the most commonly used atypical antipsychotics.

Expert opinion: Given the potential harm of not treating severe psychiatric illnesses during pregnancy, careful administration of antipsychotics is recommended for pregnant women who suffer from severe mental disorders. The most frequently used antipsychotics in pregnancy are olanzapine, risperidone and quetiapine, and do not appear to cause consistent, congenital harm to the fetus. No specific patterns of fetal limb or organ malformation related to these drugs have been reported. There is some evidence suggesting an association between antipsychotic use in pregnancy and the development of gestational diabetes. Also there appears to be an association between antipsychotic medication use in pregnancy and increased neonatal respiratory distress and withdrawal symptoms. Further studies are needed for clinicians to balance good maternal mental health, healthy pregnancies and good infant health outcomes.     

Lamotrigine use in pregnancy

Lamotrigine is a sodium-channel-modulating, antiepileptic drug (AED), which was approved in the USA in 1994 for use in partial-onset seizures. It was ultimately approved for monotherapy in 1998. Lamotrigine has gained widespread use in the USA as both an immediate and an extended-release agent. Lamotrigine is effective against a broad spectrum of seizure types and has a favorable metabolic profile, with few but significant drug interactions. Pregnancy registries in several countries have demonstrated that AED use in women with epilepsy is associated with an increased risk of fetal malformations, if the infant is exposed during the period of organogenesis. In addition, new evidence demonstrates that AEDs may affect the intellectual development of a child, as measured up until the age of 3 years. This information has made the choice of an anticonvulsant for a woman who might become pregnant significantly more important. Pregnancy registries have consistently demonstrated lamotrigine to be among the safest medications for a developing fetus, both in terms of fetal malformations and postpartum cognitive development. These findings make lamotrigine probably the first choice of AED for women wishing to become pregnant and for whom the medication is appropriate.     

Low-molecular-weight heparins in pregnancy

We conducted a systematic review, with MEDLINE and Cochrane Library data base searches and bibliographic reviews, of English-language reports describing therapy with low-molecular-weight heparin (LMWH) in pregnancy. Altogether 40 citations, excluding abstracts, were identified. When the quality of evidence was categorized according to the method outlined by the U.S. Preventive Services Task Force, 2 articles were level I, 3 were level II-1, 3 were level II-2, 4 were level II-3, 9 were level III, and the remaining 19 were classified as other (i.e., below level III). Of the 728 pregnant women and 1 postpartum woman described in the 40 citations, 340 (47%) received dalteparin, 192 (26%) enoxaparin, 108 (15%) certoparin, 54 (7%) nadroparin, 30 (4%) other LMWH, and 6 (< 1%) unspecified. The indication for LMWH in most patients (606 pregnancies, 83%) was for thromboprophylaxis. Daily doses ranged from 2500-22,000 U for dalteparin, 20 mg (2000 U)-80 mg (8000 U) for enoxaparin, 3000 U for certoparin, and 2050-15,000 U for nadroparin. Regimens included fixed dosages, increasing dosages as pregnancy progressed, dosages based on body weight, and dosages titrated according to anti-Xa levels. Duration of therapy ranged from a single dose to 476 days. Maternal anti-Xa levels were reported for 255 pregnancies. Target anti-Xa levels ranged from 0.1-0.6 U/ml and measured values from 0.0-0.7 U/ml. Major maternal findings were 18 local and generalized skin reactions, 27 bleeding complications, 9 thromboembolic events, 8 deep vein thromboses, 1 bilateral renal vein thrombosis, 4 pulmonary emboli, 1 hepatic infarction, 4 cases of thrombophlebitis, 12 cases of preeclampsia, 1 placental abruption, and 2 osteoporotic vertebral fractures. A major fetal finding was lack of anti-Xa activity in fetal or cord blood. Published experience suggests that LMWHs are generally safe and effective when administered for thromboprophylaxis during pregnancy. Until prospective, randomized, controlled trials comparing them with unfractionated heparin are performed, their benefits in pregnancy will remain inconclusive.